CPMV-Binding Peptide for HER2-Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting and delivering therapeutic agents to HER2-expressing cancers, such as breast or ovarian cancer, are limited in specificity and efficacy, particularly for chemotherapy-resistant cases.
Innovation Solution
Development of CPMV-binding peptides that can be conjugated with ant-cancer agents and targeted to HER2 receptors using a human epidermal growth factor receptor 2 (HER2)-specific peptide ligand, allowing for targeted delivery of therapeutic agents to cancer cells while avoiding non-specific cell uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy methods are used to treat cancer, then cancer cells can be targeted with therapeutic agents, but specificity is limited and non-specific cell uptake occurs leading to chemotherapy resistance
Solution Approach 1:
The patent uses CPMV nanoparticles as intermediary carriers that specifically bind to HER2 receptors on cancer cells. The CPMV particle serves as a mediator between the therapeutic payload and the target cell, enabling specific delivery through the HER2-targeting peptide while protecting the cargo and minimizing non-specific uptake by healthy cells.
Solution Approach 2:
The invention functionalizes only the exterior surface of CPMV particles with HER2-targeting peptides, while the interior maintains its porous structure for cargo loading. This localized functionalization ensures specific targeting capability without compromising the loading efficiency and release properties of the nanoparticle carrier.
2Productivity
If CPMV is used as a nanoparticle carrier for drug delivery, then therapeutic agents can be loaded and delivered to target sites, but the mechanism for specific cellular uptake needs to be established
Solution Approach 1:
The patent employs a dual-component system where CPMV particles dynamically interact with target cells through reversible binding to HER2 receptors. The flexible peptide linkers allow the particles to adapt their configuration during binding and internalization processes, enhancing both delivery efficiency and cellular uptake specificity.
Solution Approach 2:
The invention creates a composite nanoparticle system combining CPMV capsid proteins with synthetic HER2-targeting peptides and therapeutic cargo. This composite structure integrates the biocompatibility and structural stability of CPMV with the specific targeting capability of peptide ligands, achieving both efficient delivery and selective uptake.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CPMV-binding peptides enable selective targeting and uptake of ant-cancer agents by HER2-expressing cancer cells, potentially offering an effective treatment option for chemotherapy-resistant breast and ovarian cancers by enhancing the delivery of therapeutic agents.
Implementation Method 1
Applicant discloses herein a non-covalent yet CPMV-specific modification strategy
Implementation Method 2
a receptor-targeting domain, here human epidermal growth factor receptor 2 (HER2) was targeted using a peptide ligand
Data Source
AI summary
This disclosure provides a conjugate comprising a 7-mer peptide bound to the surface of a viral particle such as cowpea mosaic virus (CPMV). The c terminus of this peptide can be conjugated to desired molecules with the N terminus of the peptide interacting with CPMV surface.